Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis

Generalized anxiety disorder (GAD), characterized by pervasive and highly distressing anxiety and worries, is associated with severe impairment. Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier. In the face of this challenge, new pharmacological alternatives need to be further studied aiming at clinical improvement and better quality of life for patients. To assess the efficacy of pregabalin (PGB) compared with placebo for amelioration of anxiety symptoms in patients with GAD. A systematic literature search was performed using databases such as MEDLINE and EMBASE and other sources. The main outcome was Hedges’ g for continuous scores. We used a random-effects model. Heterogeneity was evaluated with the I2 (moderate heterogeneity was assumed if I2 was>50% and high heterogeneity if I2 was>75%) and the χ2-test (P
Source: International Clinical Psychopharmacology - Category: Psychiatry Tags: Review Article Source Type: research